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median OS from SBRT is 2.2 years (95%CI, 1.2 to 2.7 years), 
and the median OS from surgery is 5.0 years (95%CI, 3.9 to 
6.8 years). 
 
 
 
Conclusions: Our results demonstrate that SBRT after surgery 
brings about a good prognosis with low toxicity. SBRT may be 
a good treatment option for intrapulmonary recurrence after 
lung cancer surgery.  
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Purpose/Objective: Stereotactic Ablative Radiotherapy 
(SABR) has now become a primary option for medically 
inoperable patients with early stage non-small cell lung 
cancer (NSCLC). Many retrospective and prospective studies 
have showed that SABR can achieve local control rates of 
approximately 90%, offering a significant survival advantage 
over conventional radiotherapy with specific survival rates 
comparable to those of surgery. The aim of this retrospective 
study was to evaluated the clinical outcomes in patients 
affected with stage I NSCLC, medically inoperable, treated 
with SABR. 
Materials and Methods: Between 2003 and 2012, 110 
consecutive patients with stage I NSCLC were treated with 
SABR. The median age was 77 years (range 48-96 years). 
Histological/cytological diagnosis was obtained in 56 patients 
(50,9 %). The remaining 54 patients (49.1%) were included in 
the study if both FDG-PET was positive and tumor had 
increased in size at a second CT scan performed at least after 
a three months interval. Eighty-five patients (77.3%) had 
stage IA (T1N0M0 in 48 cases and T1bN0M0 in 37 cases, 
respectively) and 25 patients (22.7%) had stage IB (T2aN0M0), 
according to the 7th edition of the TNM classification and 
staging system for lung cancer. One hundred and three 
patients were medically inoperable because of the presence 
of medical comorbidities, poor pulmonary function or 
advanced age; 7 patients refused surgery. In 98 cases (89%) 
the localization of the tumor was peripheral; in 12 cases 
(11%) the localization was central. All patients were treated 
with 3D-CRT, consisting in 7-12 non-coplanar static fields 
conformed by mean of a multi leaf collimator (MLC). Dose 
and fractionation were chosen depending on size and location 
of the tumor. RTOG score were used for grading acute and 
late toxicity. 
Results:  Median follow-up time was 24.2 months (range 3-
123 months). One-year and 3-year local control was 95% and 
75%, respectively. Forty-one patients (45.1%) had at least one 
failure (local and/or nodal and/or distant), with a median 
time to any recurrence of 18.5 months. Disease free survival 
(DFS) rate at 3 years was 53%. Overall survival (OS) at 3 and 5 
years was 70% and 47%, respectively. Grade 1 acute 
pulmonary toxicity was observed in two patients (1.8%). Late 
pulmonary toxicity was recorded in 7 patients (6.3%) as: G1 in 
3, G2 in 3 and G3 in 1 patients, respectively. Seventy-four 
patients (67.3%) developed late radiological toxicity as: G1 in 
66, G2 in 7 and G3 in 1 patients, respectively. 
Conclusions: The results of this study support the routine use 
of SABR for stage I NSCLC, due to high local control and 
limited toxicity.  
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Purpose/Objective: Several investigators suggest that 
pretreatment blood parameters can be useful in determining 
the prognosis of non-small cell lung cancer (NSCLC). The 
relevance of readily available and commonly recorded blood 
parameters for long-term outcome of curative radio-
chemotherapy for NSCLC is, however, only partially 
determined.  
Materials and Methods: The analysis included 104 patients 
with stage IIIAN2 or III B non-small cell lung cancer (64 
squamous cell, 18 adenocarcinoma, 22 NOS). All patients had 
platin-based induction chemotherapy and radiotherapy with 
curative intent (60-74 Gy, 1,8-2.0 Gy/fraction). Twenty 
routinely recorded parameters from automated blood cell 
counter (blood cell number, mean cell volume, distribution 
width, hemoglobin concentration etc.) as well as erythrocyte 
sedimentation rate (ESR), osteopontin concentration (OP) and 
ratios of those parameters were considered in the analysis. 
Clinical parameters of known prognostic potential were also 
included (age, sex, general performance status, T, N stage, 
smoking history). Univariate and multivariate Cox 
proportional hazard regression model was used to select 
variables that had significant and independent impact on 
overall survival. The model performance was assessed with 
respect to 3-year overall survival by calculating the AUC 
(area under the curve) using ROC analysis. 
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Results: A multivariate model that was optimized with 
stepwise backward regression indicated that tree 
parameters: clinical N stage 2 or 3 (RR=1.85), high ESR 
(RR=1.74) and high platelet/hemoglobin ratio (RR=1.67) 
independently and negatively influenced overall survival. The 
actuarial 3-year overall survival was 27%. Patients with no 
risk features had 3-year OS of 60%, those with 1 risk factor 
had 3-year OS of 25%, while those with 2-3 risk factors had 3-
year OS of 10% (p<0.001, RR=2.08). OP correlated with ESR 
(correlation coefficient 0.42, p<0.05). The model of 3 year 
overall survival yielded an AUC of 70% (specificity 69,6%, 
sensitivity 62,2%). 
Conclusions: Platelet/hemoglobin ratio and erythrocyte 
sedimentation rate are readily available strong 
prognosticators of overall survival in curative radio-
chemotherapy for locally advanced non-small cell lung 
cancer. The outcome support the studies that suggest that 
inflammation-related parameters (such as ESR) should be 
routinely considered in determination of the prognosis of 
NSCLC.  
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Purpose/Objective: Recent trials of stereotactic 
radiotherapy (SBRT) for lung cancer exclude central lesions, 
tumors considered within or affecting the area of the 
proximal bronchial tree defined as 'a volume of 2 cm in all 
directions around proximal bronchial tree'. Several series for 
central tumors have been published with various doses and 
fractionation. These series often proposed a scheme with a 
Biological Effective Dose (BED) less than 100 Gy to minimize 
the risk of toxicity. We investigated our original institutional 
experience using SBRT for central lung tumor with a scheme 
delivering 75 Gy in 5 fractions of 15 Gy leading to a BED of 
187.5 Gy.  
Materials and Methods: Our institutional SBRT database 
retrospectively collected demographic and treatment-related 
data from all patients treated at our Center. We analyzed all 
patients with central lung tumors treated with SBRT between 
September 2008 and September 2012. Local control (LC) and 
overall survival (OS) were calculated using Kaplan- Meier 
estimates. Toxicity was graded using the Radiation Therapy 
Oncology Group Common Toxicity Criteria. Tumor response 
was scored using Response Evaluation Criteria in Solid Tumors 
v1.1. Predictors for toxicity, LC, and OS were analyzed using 
Cox proportional hazard regression models. 
Results: A total of 43 central lesions in 41 patients (23 with 
primary, 12 with metastatic tumors, 6 no biopsy proven) 
were treated. Median age was 71 years (range: 51-88) and 
median follow up was 24.4 months (1-67). Seventeen patients 
had prior surgery: 10 lobectomies, 3 pneumonectomies, 4 
wedge resections. Radiation was delivered in 5 equal 
fractions of 12 to 15 Gy each to a median prescription isodose 
line of 78.9% (range, 68-80%). Thirty-four tumors (79%) were 
treated with the original regime (75 Gy= 5 X 15 Gy). In order 
to respect the dose constraints of organs at risk we have 
changed the dose per fraction for 9 tumors (21%) (n= 4: 70 
Gy/5 Fr; n=5: 60 Gy/5 Fr). Overall, there were 4 local 
failures resulting in 1-year LC rate and 3-years local LC rate 
of 82.2% and 78.5% respectively. Grade 3 toxicities were 
dyspnea (n = 2), pneumonia (n = 3), pleural effusion (n = 1) 
and parietal pain (n = 1). One patient previously treated by 
pneumonectomy died of dyspnea grade V 12.9 months after 
treatment. The actuarial 1-year and 3-year overall survival 
was respectively 89.4% and 52.7%. 
Conclusions: SBRT for central lung tumors offers high rates 
of local control and acceptable toxicity rates comparable to 
published data for peripheral tumors. 
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Purpose/Objective: To describe a new technique of External 
Radiotherapy Hypofractionated with immobilised patient and 
with the Lung arrested, which we have set into motion in our 
centre and which we have called: 'Arrested Lung Ablative 
Radiotherapy' (ALART). The second objective was to 
investigate the possible parameters of movement in the 
treatment. 
Materials and Methods: We use this technique in four 
patients, treated with RT-54Gy (3 fractions); IMRT: 34 and 
27Gy two lesions (1 fraction), RT-32Gy (1 fraction) and RT-
30Gy (1 fraction). To carry out the technique, general 
anaesthesia is applied with mechanical ventilation until we 
arrested the lung, to achieve that we use a portable extra-
corporeal membrane oxygenation (ECMO) device 
(Cardiohelp™-Maquet©) with a Normo-hypothermia module by 
femoral (arterio-venous) cannulation. For the transport and 
immobilization of the patient we used the Image Provider® 
(SIHO©) transfer trolley with vacuum mattress immobilizer 
and an abdominal compressor frame with the ECMO device, 
keeping the lung arrested and immobilized from the Plan-CT 
to the CT-post-Treatment. The calculation was done with a 
TPS XiO (CMS-Elekta). For the positioning of the patient we 
used a stereotaxic system Exactrac® (Brainlab©) and 
ConeBeam (Elekta). The LINAC was a Primus (Siemens) and 
Synergy (Elekta) using the portal image system in movie 
mode and the Exactrac® to monitorized the movement of the 
patient in the Siemens LINAC and the ConeBeam imaging for 
the Synergy LINAC. We fused through rigid fusion the pre-CT 
and the Post-CT at the level of the tumour and at a global 
level. In each of the fusions we transferred PTVs & GTVs and 
we measured the distances between the center of the 
volumes. 
